Better Decisions, Faster

Analyzing the pharmacokinetic (PK) properties of your compound early and throughout the development process is critical to subsequent decision-making and a drug’s ultimate success. PK studies using animal models and rapid analytical methods provide fast, accurate results and to help guide, more extensive GLP and/or clinical studies. Covance experts will work with you to predict how your drug will react in humans before it reaches first-in-human trials, allowing you to make important decisions on your drug’s development strategy.

Experience and Resources

When you partner with Covance, you’ll have access to innovation, insight and expertise derived from more than 50 years experience providing drug metabolism services to the pharmaceutical industry. This includes thousands of GLP-compliant and thousands more non-GLP metabolism, bioanalytical and safety studies for clients worldwide. Our dedicated lab facilities in around the world offer you the flexibility and capacity for any study need.

To expedite your results, we offer a solution combining PK in-life, discovery bioanalytical and PK data analysis. Your analytical needs will be covered with our tiered approach that includes rapid turnaround to more rigorous, near-GLP testing. With the option of selecting in-life and bioanalysis in phases or as a part of a comprehensive customized study package, you will always benefit from having a single Covance contact for your study. Other resources include:

- Study directors assigned specifically to lead preclinical in vivo PK studies
- Full-time pharmacokinetists with extensive experience
- Dedicated discovery bioanalytical laboratory and global team with more than 30 years of experience conducting discovery bioanalysis for thousands of compounds

Animal Capacity and Capabilities

When you partner with Covance, you’ll have access to:

- Facilities to support longer-term studies using immunocompromised animals, including nude and SCID mice
- Rodents available on demand
Model colonies at our sites in Madison, Alice, Greenfield and Harrogate are available for immediate PK Studies including:

- 350 cynomolgus monkeys
- 150 beagle dogs
- 10 rhesus monkeys

Access to canulated animal models suppliers

A variety of surgically canulated animal models, including bile-duct and portal vein canulated dogs and monkeys

An industry-leading laparoscopic surgical technique for taking serial liver biopsy samples which reduces the use of animals by 50-80%

Bioanalytical Support

Our tenured scientists have experience using progressive technology platforms and understand what it takes to move your molecule from discovery to your next milestone. We continue to invest to offer you the latest technologies and philosophies including:

- Triple quadruple mass spectrometers to provide you efficient implementation of sensitive and specific quantitative methods
- Q-Exactive™ to meet your exact mass needs
- High-throughput support with the use of robotics and 96-well technology
- Watson® version 7.4 software for efficient data management and transfer

PK Analysis

Understanding of the data and its implications will help you design your clinical strategy. Our team provides expert analysis of PK data using non-compartmental models and validated Phoenix® WinNonlin® providing you with insight and direction.

For more information on how our preclinical PK services can support your drug development efforts, please call us at +1.888.COVANCE or +44.1423.500888.

Learn more about our drug development solutions at www.covance.com

Covance Inc., headquartered in Princeton, NJ, USA is the drug development business of Laboratory Corporation of America Holdings (LabCorp). COVANCE is a registered trademark and the marketing name for Covance Inc. and its subsidiaries around the world.

The Americas  + 1.888.COVANCE  + 1.609.452.4440
Europe / Africa  + 00.800.2682.2682  Asia Pacific  + 800.6568.3000
© Copyright 2015 Covance Inc.  SPMET023-0615